Prokidney

Prokidney Minority Interest

Minority Interest (Non-Controlling Interest) of Prokidney (PROK) as of Nov 15, 2026.

Minority Interest

-USD

Last updated:

Minority Interest (Non-Controlling Interest) of Prokidney is 2026 - USD. Minority Interest (Non-Controlling Interest) of Prokidney was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prokidney Stock analysis

What does Prokidney do? Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease. Prokidney is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prokidney stock

On Eulerpool you can find the complete historical development of Minority Interest (Non-Controlling Interest) Prokidney since 2006 – with annual values, charts, and detailed analysis.

Minority interest represents the portion of subsidiaries not owned by the parent company. It reflects third-party ownership stakes in consolidated entities.

Minority Interest (Non-Controlling Interest)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Minority Interest (Non-Controlling Interest)'s Prokidney historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Prokidney

All Key Metrics — Prokidney